6-(4-{[4-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]methyl}phenyl)-5-phenylpyridine-3-carbonitrile | 791850-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 6-(4-{[4-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]methyl}phenyl)-5-phenylpyridine-3-carbonitrile
• 英文别名: 6-[4-[[4-(1H-benzimidazol-2-yl)piperidin-1-yl]methyl]phenyl]-5-phenylpyridine-3-carbonitrile
• CAS: 791850-63-0
• 化学式: C₃₁H₂₇N₅
• 分子量: 469.589
• InChiKey: ORBNIMIXUBKTHN-UHFFFAOYSA-N

物化性质

• 沸点：
  680.9±55.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-(4-{[4-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]methyl}phenyl)-5-phenylpyridine-3-carbonitrile 在 sodium azide 、 zinc dibromide 作用下， 以 水 为溶剂， 反应 0.33h， 生成 2-[1-({4-[3-phenyl-5-(1H-1,2,3,4-tetrazol-5-yl)pyridin-2-yl]phenyl}methyl)piperidin-4-yl]-1H-1,3-benzodiazole
  参考文献：
  名称：

  Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors

  摘要：

  This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold. Compounds from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.062
• 作为产物：
  描述：

  6-Hydroxy-5-phenyl-nicotinonitrile 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 MP-BH₃(CN) 、 caesium carbonate 作用下， 以 四氢呋喃 、 吡啶 、 水 为溶剂， 反应 0.17h， 生成 6-(4-{[4-(1H-1,3-benzodiazol-2-yl)piperidin-1-yl]methyl}phenyl)-5-phenylpyridine-3-carbonitrile
  参考文献：
  名称：

  Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors

  摘要：

  This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold. Compounds from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.12.062

文献信息

• Inhibitors of akt activity
  申请人：Bilodeau T Mark

  公开号：US20070043001A1

  公开（公告）日：2007-02-22

  The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及化合物，其中包含取代的吡啶基团，可抑制Akt蛋白激酶的活性。本发明还涉及含有本发明化合物的化疗组合物和治疗癌症的方法，包括给予本发明化合物的治疗方法。
• INHIBITORS OF AKT ACTIVITY
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1622616B1

  公开（公告）日：2011-06-15
• US7579355B2
  申请人：——

  公开号：US7579355B2

  公开（公告）日：2009-08-25
• [EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITE AKT
  申请人：MERCK & CO INC

  公开号：WO2004096131A2

  公开（公告）日：2004-11-11

  The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
• Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors
  作者：Zhijian Zhao、William H. Leister、Ronald G. Robinson、Stanley F. Barnett、Deborah Defeo-Jones、Raymond E. Jones、George D. Hartman、Joel R. Huff、Hans E. Huber、Mark E. Duggan、Craig W. Lindsley

  DOI：10.1016/j.bmcl.2004.12.062

  日期：2005.2

  This letter describes the discovery of a novel series of dual Akt1/Akt2 kinase inhibitors, based on a 2,3,5-trisubstituted pyridine scaffold. Compounds from this series, which contain a 5-tetrazolyl moiety, exhibit more potent inhibition of Akt2 than Akt1. (C) 2005 Elsevier Ltd. All rights reserved.